Investment Thesis
Agios Pharmaceuticals exhibits severe fundamental deterioration with operating losses exceeding 872% margin and negative free cash flow of -$377.3M despite revenue growth. The company is burning substantial cash reserves with only $89.1M in liquidity while operating at massive losses, indicating severe clinical or commercial execution failures. Revenue growth cannot offset the structural unprofitability and alarming cash burn trajectory.
AGIO Strengths
- Strong balance sheet with $1.2B stockholders' equity and minimal debt
- Exceptional liquidity position with 11.46x current ratio
- Revenue growing 48% YoY indicating product demand or new commercial traction
AGIO Risks
- Operating margin of -873.9% with net margin of -764% shows business is fundamentally unprofitable
- Negative free cash flow of -$377.3M annually will deplete $89.1M cash reserve in under 3 months at current burn rate
- Operating cash flow of -$373M indicates core business cannot fund operations, suggesting failed drug development pipeline or major clinical setbacks
- Diluted EPS of -$7.12 with 161% YoY deterioration indicates worsening losses despite revenue growth
Key Metrics to Watch
- Cash runway and time to zero liquidity at current burn rate
- Operating cash flow trajectory and path to cash flow breakeven
- Revenue growth sustainability and pipeline advancement milestones
AGIO Financial Metrics
AGIO Profitability Ratios
AGIO Balance Sheet & Liquidity
AGIO 5-Year Financial Trend
5-Year Trend Summary: AGIOS PHARMACEUTICALS, INC.'s revenue has declined by 73% over the 5-year period, indicating business contraction. The most recent EPS of $-6.33 indicates the company is currently unprofitable.
AGIO Growth Metrics (YoY)
AGIO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.0M | -$81.5M | $-1.78 |
| Q2 2025 | $8.6M | -$81.5M | $-1.69 |
| Q1 2025 | $8.2M | -$81.5M | $-1.45 |
| Q3 2024 | $7.4M | -$81.0M | $-1.64 |
| Q2 2024 | $6.7M | -$81.0M | $-1.51 |
| Q1 2024 | $5.6M | -$81.0M | $-1.45 |
| Q3 2023 | $3.5M | -$81.0M | $-1.49 |
| Q2 2023 | $5.6M | -$81.0M | $-1.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AGIO Capital Allocation
AGIO SEC Filings
Access official SEC EDGAR filings for AGIOS PHARMACEUTICALS, INC. (CIK: 0001439222)